Education
About Us
Working with TipRanks
Follow Us
EKSO BIONICS (EKSO)
NASDAQ:EKSO
EKSO Stock Chart & Stats
$8.71
-$0.08(-9.64%)
At close: 4:00 PM EST
$8.71
-$0.08(-9.64%)
Day’s Range― - ―
52-Week Range$2.73 - $12.70
Previous CloseN/A
Volume1.71M
Average Volume (3M)56.84K
Market Cap
$29.55M
Enterprise Value$23.14M
Total Cash (Recent Filing)$2.72M
Total Debt (Recent Filing)$3.02M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Feb 19, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding3,392,723
10 Day Avg. Volume46,910
30 Day Avg. Volume56,843
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)14.52
Price to Sales (P/S)10.29
P/FCF Ratio-18.67
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue1.57
Enterprise Value/Gross Profit2.93
Enterprise Value/Ebitda-2.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst OutlookAnalyst maintained a Buy rating and raised the price target after revenue beat and a smaller-than-expected loss per share, reflecting increased confidence in the company’s outlook.
Merger/AcquisitionProposed merger with Applied Digital Cloud could provide access to larger capital and cloud infrastructure to accelerate commercialization and scale of the company's exoskeleton technology.
Revenue RecoverySequential recovery in sales with notable revenue growth and improved gross margins suggests previous demand delays were idiosyncratic and core business momentum is returning.
Bears Say
Divestiture RiskPlans to pursue a strategic sale or divestiture of the legacy MedTech business create execution risk and uncertainty about how proceeds and focus will be redeployed.
Rating And Valuation PressureDowngrade to Neutral after significant price appreciation removes previous analyst price support and may increase stock volatility during the ongoing strategic review and possible transactions.
Strategic Shift RiskManagement's move away from commercializing exoskeletons for health and industrial uses raises concerns about dilution of the company's core competitive advantage and future revenue mix.
EKSO BIONICS News
EKSO FAQ
What was EKSO BIONICS’s price range in the past 12 months?
EKSO BIONICS lowest stock price was $2.73 and its highest was $12.70 in the past 12 months.
What is EKSO BIONICS’s market cap?
EKSO BIONICS’s market cap is $29.55M.
When is EKSO BIONICS’s upcoming earnings report date?
EKSO BIONICS’s upcoming earnings report date is Feb 19, 2026 which is in 25 days.
How were EKSO BIONICS’s earnings last quarter?
EKSO BIONICS released its earnings results on Oct 28, 2025. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.965 by $0.425.
Is EKSO BIONICS overvalued?
According to Wall Street analysts EKSO BIONICS’s price is currently Overvalued.
Does EKSO BIONICS pay dividends?
EKSO BIONICS does not currently pay dividends.
What is EKSO BIONICS’s EPS estimate?
EKSO BIONICS’s EPS estimate is -0.29.
How many shares outstanding does EKSO BIONICS have?
EKSO BIONICS has 3,392,723 shares outstanding.
What happened to EKSO BIONICS’s price movement after its last earnings report?
EKSO BIONICS reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.965. Following the earnings report the stock price went up 9.148%.
Which hedge fund is a major shareholder of EKSO BIONICS?
Currently, no hedge funds are holding shares in EKSO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
EKSO BIONICS
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.